Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A 23 year old female who experienced Telogen Effluvium due to stress 4 years ago, but her hair is still not back to normal. She is looking for treatments such as Minoxidil and dermarolling that may help with the thinning patches in her hair.

The user is using oral minoxidil and dutasteride for hair loss and observed changes in blood pressure after taking oral minoxidil. They experienced no visible symptoms from topical minoxidil, finasteride, or other treatments and are seeking feedback on whether these blood pressure changes are typical for oral minoxidil users.

A 29-year-old male with diffuse thinning plans to start minoxidil and finasteride soon but is concerned about potential shedding before a big event in late April/early May. He is considering whether to start treatment now or wait until after the event.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about hair loss treatments, including dermarolling, Minoxidil, Finasteride, and RU58841. Users discuss their experiences, side effects, and application methods for these treatments.

The conversation discusses the effectiveness of Botox and PRP for hair regrowth. Users share experiences and insights on these treatments.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

A user is experiencing uneven hair thinning and has tried topical minoxidil without success and finasteride with adverse effects. They are considering microneedling and PRP treatments while avoiding finasteride, and another user suggests trying dutasteride as an alternative.

The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.

People on finasteride or dutasteride cannot donate blood due to the risk of birth defects if the blood is given to a pregnant woman. It's advised to stop finasteride for a month and dutasteride for six months before donating.

The conversation is about the struggles of dealing with diffuse thinning at a young age and the lack of significant improvement after using treatments like finasteride and minoxidil. Some suggest additional methods like derma rolling, microneedling, and hair fibers, while others share their own experiences and encourage persistence with treatment.

A user shared their experience with high cholesterol, glucose, and potential metabolic syndrome after using Finasteride and Dutasteride for hair loss. They plan to improve their health with diet and exercise before considering medication.

User is using a topical solution with .1% finasteride, 6% minoxidil, and .0125% tretinoin for hair loss, along with a .25 derma roller once a week. They are concerned about the necessity and potential side effects of using the derma roller.

Oral minoxidil is effective for hair loss but can cause cardiovascular side effects, such as pericardial effusion, especially in those with genetic predispositions. Starting with low doses and monitoring cardiovascular health are advised to reduce risks.

The user is experiencing diffuse hair thinning despite using dutasteride and minoxidil for over five years and is considering adding oral minoxidil, microneedling, and nizoral to their regimen. They are concerned about the effectiveness and side effects of these treatments, especially with an upcoming event.

User discusses a promising topical Procyanidin B2 treatment for hair loss. Users share mixed experiences and mention effective treatments like finasteride, minoxidil, and LLLT.

Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The user has been using 5% minoxidil once daily and microneedling with a 1.5 mm dermaroller weekly for three months, considering increasing minoxidil usage but avoiding finasteride due to libido concerns. Another person suggests considering other treatments like RU58841, alfatradiol, topical finasteride, clascoterone, or saw palmetto since not using a DHT blocker could be less effective.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

The user is experiencing low libido and mood swings after starting a low dose of topical finasteride. They are considering further blood tests to investigate low testosterone levels and other hormonal factors.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

A 32-year-old male with diffuse thinning and seborrheic dermatitis has been using finasteride for 8 months without improvement. He is considering COQ10 + PQQ supplements for scalp inflammation and hair loss.

A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

The user has been using finasteride and minoxidil for 11 months but is experiencing increased hair loss and no signs of improvement. Another user shares a similar experience and mentions iron deficiency and thyroid issues affecting hair loss despite using the treatments.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.